A third of patients with treatment-resistant non-small cell lung cancer (NSCLC) responded to second-line therapy with afatinib and cetuximab (Erbitux), investigators reported here.


The combination led to a median progression-free survival of 4.7 months at the maximum tolerated dose, and only a handful of the 100 patients treated with the combination had progressive disease as best response.

Via Cancer Commons